Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Valuation Overview•Is Liminatus Pharma, Inc. Class A Common Stock Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 5/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street sentiment is generally neutral. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
LIMN struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company maintains stable top-line performance paired with stable bottom-line earnings.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | |
| EBITDA | -$1.1M | — | -3.1% | — | — | |
| Net Income | -$1.1M | -251.4% | -51.6% | — | — | |
| EPS (Diluted) | $-0.05 | -7.5% | — | — | — | |
| Free Cash Flow | -$2.0M | -221.2% | -125.6% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Margin | — | — | — | — |
| FCF Margin | — | — | — | — |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | — | $-0.03 | — | ||
| Q1'26 | — | $-0.03 | — | ||
| Q4'25 | — | $-0.07 | — | ||
| Q4'25 | — | $-0.05 | — |
Total return is -99.6% (1Y), lagging the benchmark by -120.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -83.9% | -91.2% | — |
| 1Y | -99.6% | -120.5% | — |
| 3YCAGR | -72.6% | -91.4% | — |
| 5YCAGR | -54.0% | -65.0% | — |
| 10YCAGR | -32.2% | -45.5% | — |
The S&P 500 is at 30.6x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Liminatus Pharma, Inc. Class A Common Stock (LIMN) valuation, health, and returns.
Liminatus Pharma, Inc. Class A Common Stock valuation is being assessed using available models.
Valuation anchors are currently not available.
Liminatus Pharma, Inc. Class A Common Stock displays poor financial health with a composite quality score of 5/100, supported by a Altman Z-Score of -100.0 (distress zone), Piotroski F-Score of 1/9.
Liminatus Pharma, Inc. Class A Common Stock does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Liminatus Pharma, Inc. Class A Common Stock's current growth trajectory is Stable. The company achieved N/A 1Y revenue growth and -7.5% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
Investment risks for Liminatus Pharma, Inc. Class A Common Stock include: -99.4% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.28x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.